nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.02.2014

Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay

verfasst von: Wilmare Gouws, Elsabie Botha, Adele Visser

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The chromogenic FVIII assay is currently considered the gold standard for quantitation of factor VIII levels in both haemophilia A patients and as part of screening for thrombophilia. A method validation and evaluation of clinical utility within a routine diagnostic laboratory was undertaken by comparing the currently used one-stage assay to a commercially available chromogenic assay (Siemens, Johannesburg, South Africa). In total, 60 samples were included in this study to encompass the whole diagnostic range of the assay. Both low and high values showed very good correlation on linear regression analysis with correlation coeffients of 0.949 and 0.888 respectively. However, the lower detection limit of the Siemens Chromogenic assay was 1.5 IU/dL rendering it impossible to utilize in the setting of classifying a haemophilia A patient in terms of disease severity. Although the Siemens FVIII chromogenic assay shows excellent correlation to the currently used one-stage assay, the relatively high detection limit restrict implementation as a stand-alone assay in a routine diagnostic laboratory.

Chandler W, Ferrell C et al (2003) Comparison of three methods for mesauring factor VIII levels in plasma. Am J Clin Pathol 120:34–39PubMedCrossRef

Koster T, Blann A et al (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurance of deep-vein thrombosis. Lancet 345(8943):152–155PubMedCrossRef

Barrowcliffe T, Raut S et al (2002) Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization and recommendations. Semin Thromb Hemost 28(3):247–256PubMedCrossRef

Barrowcliffe T (1984) Methodology of the two-stage assay of Factor VIII (VIII:C). Scand J Haematol 33(Suppl 41):25–38

Over J (1984) Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haematol 33(Suppl 41):13–24

Rosen S, Friberger P et al (1986) A new chromogenic assay for determination of human factor VIII:C activity. College of American Pathologists, Skokie

Denson K, Biggs R (1976) Laboratory diagnosis, tests of clotting function and their standardization. Lippincott, Oxford

Peerlinck K, Jacquemin M (2010) Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia 16(Suppl 5):100–106PubMedCrossRef

Hill N, Deam S et al (2005) Mutation analysis of 51 patients with haemophilia A: report of ten novel mutations an correlation between genotype and clinical phenotype. Haemophilia 11:13–141CrossRef

10.

Keeling D, Sukhu K et al (1999) Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His 1954—Leu substitutution in the factor VIII A3 domain. Br J Haematol 105:1123–1126PubMed

11.

Kemball-Cook G, Tuddenham E et al (1998) The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res 26:216–219PubMedCentralPubMedCrossRef

12.

Lyall H, Hill M et al (2008) Tyr346-Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype—is this mild haemophilia A? Haemophilia 14:78–80PubMed

13.

Pipe S, Saenko E et al (2007) Haemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein–protein interactions within the triplicated A domains of thrombin-activated factro VIIIa. Blood 97:685–697CrossRef

14.

Rudzki Z, Duncan E et al (1996) Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 94:400–406PubMed

15.

Schwaab R, Oldenburg J et al (2000) Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694IIe) in a large Danish family. Br J Haematol 109(3):523–528PubMed

16.

Gilmore R, Harmon S et al (2010) Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 16:671–674PubMed

17.

Mumford A, Laffan M et al (2002) A Tyr346–> Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 118(2):589–594PubMed

18.

Poulsen A, Pedersen L et al (2009) Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre. Haemophilia 15:285–289PubMedCrossRef

19.

ICH (1995) Validation of analytical procedures: text and methodology. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH, Geneva

20.

Collazo V, Alonso C et al (2012) Validation of an automated chromogenic assay of potency of factor VIII in commercial concentrates. Int J Lab Hematol 35(1):38–45PubMedCrossRef

21.

White G, Rosendaal F et al (2001) Definitions in hemophilia. recommendations of the scientific subcommittee on FVIII and factor IX of the SCC and ISTH. Thromb Haemost 85:560PubMed

22.

Begbie M, Notley C et al (2000) The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 84(2):216–222PubMed

23.

Noe D, Murphy P et al (1989) Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol 257(1):49–56

24.

Bjorkman S, Blanchette V et al (2010) Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 8(4):730–736PubMedCentralPubMedCrossRef

25.

Hathaway, W., M. Christian, et al. (1983). “Variant mild haemophilia. Discrepancy in one stage and two stage factor VIII assays.” Thromb Haemost (Suppl 50): 357

26.

Parquet-Gernez A, Mazurier C et al (1988) Fuctional and immunological assays of FVIII in 133 haemophiliacs—characterization of a subgroup of patients with mild haemohilia A and descrepancy in 1- and 2-stage assays. Thromb Haemost 59:202–206PubMed

27.

Duncan E, Duncan B et al (1994) Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of paitents with haemophilia A. Br J Haematol 87:846–848PubMed

28.

Goodeve A, Peake I (2003) The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 29:23–30PubMedCrossRef

29.

Mazurier C, Gaucher C et al (1997) Mutations in the FVIII gene in seven families with haemophilia A. Br J Haematol 96:426–427PubMed

30.

Roelse, J., R. de-Laaf, et al. (1999). Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a Glu720–> Lys substitution in factor VIII. Thromb Haemost. doi:10.1111/j.1365-2141.2007.06935.x

31.

Goodeve, A., J. Hinks, et al. (2001). Unusual discrepant factor VIII:C assays in haemophilia A patients iwth Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost. doi:10.1111/j.1365-2516.2011.02509.x

32.

Trossaert M, Boisseau P et al (2011) Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 9:524–530PubMedCrossRef

33.

European Pharmacopoiea (2010) Assay of human coagulation factor VIII (01/2008:20704) and monograph human coagulation factor VIII (01/2010:0275). E. D. f. t. Q. o. M. HealthCare, Strassbourg

34.

Cid A, Calabuig M et al (2008) One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 14:1049–1054PubMedCrossRef

35.

Plug I, Mauser-Bunchoten E et al (2006) Bleeding in carriers of hemophilia. Blood 108(1):52–56PubMedCrossRef

36.

Verbruggen B, Meijer P et al (2008) Diagnosis of factor VIII deficiency. Haemophilia 14(Suppl 3):76–82PubMedCrossRef

Titel: Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay
verfasst von: Wilmare Gouws
Elsabie Botha
Adele Visser
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-013-0910-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD

Retinal artery occlusions in children

Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation

Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage

D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy